Latest Revenue Guidance News

Aroa Biosurgery delivered a robust September quarter with strong cash flow and record sales of its Myriad product, while reaffirming its FY26 revenue and EBITDA guidance. The company also highlighted a promising US Medicare reimbursement proposal for its Symphony product.

Cogstate Limited reports a record-breaking quarter with sales contracts soaring 88% year-on-year, driven by expanding markets and new therapeutic areas. The company signals continued investment in growth initiatives, including AI and Asia-Pacific expansion, while projecting a strong first half of FY26.

Telix Pharmaceuticals reports a robust 53% revenue jump in Q3 2025 and raises its full-year guidance, underpinned by key reimbursement wins and expanding clinical programs.

Resonance Health reveals a robust growth strategy targeting $17 million revenue by FY26, powered by AI-enhanced medical imaging and global clinical trial services expansion.

PlaySide Studios has extended its development contract with Meta Platforms for Horizon Worlds by 12 months, reinforcing its revenue outlook through 2026.

NRW Holdings has completed its acquisition of Fredon Industries, integrating 2,500 new employees and enhancing its electrical and mechanical services portfolio. The company has updated its FY26 guidance, projecting revenue above $4 billion and underlying EBITA between $255 million and $265 million.

Bravura Solutions has raised its FY26 revenue and cash EBITDA guidance, citing a strong British pound and increased project activity in EMEA as key growth drivers.

Telix Pharmaceuticals has secured FDA agreement on a resubmission plan for its glioma imaging agent TLX101-CDx, aiming for a Q4 2025 filing that includes additional efficacy data. The FDA signals likely expedited review, underscoring the unmet medical need.

Amaero Ltd has updated its FY2026 financial guidance, forecasting revenue between A$30 million and A$35 million; a staggering 800%-900% increase year-over-year; and announced a A$50 million capital raise to expand production capacity and reduce costs.

Biome Australia Limited projects its Q1 FY26 sales revenue to exceed $5.5 million, breaking its previous quarterly record and signaling continued momentum in the microbiome health sector.

Bioxyne Limited projects FY2026 revenue between $65 million and $75 million, driven by expansion in Australian medical cannabis and a landmark $5.8 million contract in Germany.

MedAdvisor reported a 36% revenue drop in FY25, driven by US health program setbacks, and sold its ANZ business to focus on restructuring its US operations.